Cellectis SA
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France. Show More...
-
Website https://www.cellectis.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 1.46 USD
-
Last Updated 30-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share USD -2.19 -1.45 -3.7 -0.67 -1.91 -2.78 -1.93 -2.41 -1.58 Dividends USD Payout Ratio % * Shares Mil 14.0 20.0 21.0 26.0 34.0 35.0 36.0 41.0 42.0 42.0 Book Value Per Share * USD 7.65 8.05 7.85 10.15 8.02 7.81 Free Cash Flow Per Share * USD 1.01 -0.56 -1.18 -1.53 -2.35 Return on Assets % -13.36 -30.72 -23.85 -105.87 0.02 -8.32 -18.17 -29.95 -18.88 -21.09 -13.58 Financial Leverage (Average) 1.38 3.56 1.46 6.35 2.26 1.3 1.21 1.25 1.22 1.48 1.42 Return on Equity % -17.39 -70.9 -50.8 -196.28 0.06 -12.43 -22.84 -36.87 -23.28 -28.19 -18.47 Return on Invested Capital % -17.19 -39.23 -29.67 -173.52 -0.36 -12.78 -23.23 -37.48 -25.22 -27.53 -16.8 Interest Coverage -71.54 -38.74 -198.05 12.5 -969.1 -43.21 -26.07 Current Ratio 2.79 2.62 1.81 0.86 1.76 4.34 5.56 7.42 10.4 6.25 7.71 Quick Ratio 2.59 2.45 1.78 0.83 1.72 4.29 5.43 7.16 10.11 6.01 7.43 Debt/Equity 0.02 1.82 0.06 0.67 0.05 0.15 0.15